Effect of increasing the infliximab dose in rheumatoid arthritis

被引：0
作者：
Schmalzing, M. [1 ]
机构：
[1] Med Univ Klin, Abt Innere Med Hamatol Onkol Immunol Rheumatol Pu, D-72076 Tubingen, Germany
来源：
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2010年 / 69卷 / 05期
关键词：
CLINICAL-PRACTICE; ESCALATION; METHOTREXATE; AGENTS;
D O I：
10.1007/s00393-009-0557-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：450 / +
页数：3
相关论文
共 13 条
  • [1] Dose escalation of the anti-TNF-α agents in patients with rheumatoid arthritis.: A systematic review
    Ariza-Ariza, R.
    Navarro-Sarabia, F.
    Hernandez-Cruz, B.
    Rodriguez-Arboleya, L.
    Navarro-Compan, V.
    Toyos, J.
    [J]. RHEUMATOLOGY, 2007, 46 (03) : 529 - 532
  • [2] Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial
    Clair, EWS
    van der Heijde, DMFM
    Smolen, JS
    Maini, RN
    Bathon, JM
    Emery, P
    Keystone, E
    Schiff, M
    Kalden, JR
    Wang, B
    DeWoody, K
    Weiss, R
    Baker, D
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (11): : 3432 - 3443
  • [3] The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis - Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
    Clair, EWS
    Wagner, CL
    Fasanmade, AA
    Wang, B
    Schaible, T
    Kavanaugh, A
    Keystone, EC
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (06): : 1451 - 1459
  • [4] A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study
    Durez, P
    Van den Bosch, F
    Corluy, L
    Veys, EM
    De Clerck, L
    Peretz, A
    Malaise, M
    Devogelaer, JP
    Vastesaeger, N
    Geldhof, A
    Westhovens, R
    [J]. RHEUMATOLOGY, 2005, 44 (04) : 465 - 468
  • [5] Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
    Finckh, A.
    Simard, J. F.
    Gabay, C.
    Guerne, P. -A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (06) : 746 - 752
  • [6] Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns
    Flendrie, M.
    Creemers, M. C. W.
    van Riel, P. L. C. M.
    [J]. RHEUMATOLOGY, 2007, 46 (01) : 146 - 149
  • [7] Infliximab and methotrexate in the treatment of rheumatoid arthritis
    Lipsky, PE
    van der Heijde, DMFM
    St Clair, EW
    Furst, DE
    Breedveld, FC
    Kalden, JR
    Smolen, JS
    Weisman, M
    Emery, P
    Feldmann, M
    Harriman, GR
    Maini, RN
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1594 - 1602
  • [8] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial
    Maini, R
    St Clair, EW
    Breedveld, F
    Furst, D
    Kalden, J
    Weisman, M
    Smolen, J
    Emery, P
    Harriman, G
    Feldmann, M
    Lipsky, P
    [J]. LANCET, 1999, 354 (9194) : 1932 - 1939
  • [9] Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy
    Pavelka, K.
    Jarosova, K.
    Suchy, D.
    Senolt, L.
    Chroust, K.
    Dusek, L.
    Vencovsky, J.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (08) : 1285 - 1289
  • [10] Double-blinded infliximab dose escalation in patients with rheumatoid arthritis
    Rahman, Mahboob U.
    Strusberg, Ingrid
    Geusens, Piet
    Berman, Alberto
    Yocum, David
    Baker, Daniel
    Wagner, Carrie
    Han, John
    Westhovens, Rene
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1233 - 1238
12